– USA, MA – Be Biopharma, whose mission is to pioneer the emerging new class of engineered B cells as medicines, today announced the appointment of Dr. Jay Backstrom (M.D., M.P.H.) to its Board of Directors.
“Jay’s exceptional clinical development acumen adds an important skill set to our Board of Directors as we develop our B cell medicine platform towards the clinic. I’m excited for Jay to join the team and to benefit from the breadth and depth of his drug development knowledge as we advance our science for the benefit of patients with serious, life-threatening diseases,” said CEO, Dr. Joanne Smith-Farrell.
About Dr. Jay Backstrom
Dr. Jay Backstrom joins the Be Bio team with over 30 years of experience in research and development. He recently served as EVP, Head of Research and Development at Acceleron and was previously CMO and Head of Regulatory Affairs at Celgene, where he joined in 2008 as VP of Clinical Research and Development, with a focus in hematology and oncology. Prior to Celgene, he served as VP of Global Medical Affairs and Safety at Pharmion. Dr. Backstrom began his career at Marion Merrell Dow and continued as part of its successor companies including Hoechst Marion Roussel. Prior to his professional career in the biotech industry, Dr. Backstrom served as Staff Physician and Medical Director of the Samuel U. Rodgers Community Health Center in Kansas City, Missouri.
“I look forward to joining Be Bio’s Board of Directors and supporting this pioneering B cell therapy company through the next phase of growth and development towards the clinic,” commented Dr. Jay Backstrom. “It’s an incredibly exciting time for the company as we advance transformative science that will unleash the immense power of the B cell, endeavoring to make a substantial impact on patients across a variety of life-threatening diseases.”
Dr. Backstrom holds an M.D. from Temple University School of Medicine and received post-graduate training in Internal Medicine at Temple University Hospital. He also earned a Master’s in Public Health from Saint Louis University School of Public Health.
About Be Biopharma
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.
For more information : https://www.be.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.